The Journal of Bone and Joint Surgery (American). 2008;90:23-33.
doi:10.2106/JBJS.F.01416
© 2008 The Journal of Bone and Joint Surgery, Inc.
Does Botulinum Toxin A Combined with Bracing Prevent Hip Displacement in Children with Cerebral Palsy and "Hips at Risk"?A Randomized, Controlled Trial
H. Kerr Graham, MD, FRCS(Ed), FRACS1,
Roslyn Boyd, PhD2,
John B. Carlin, PhD2,
Fiona Dobson, BSc, PhD1,
Kevin Lowe, MD3,
Gary Nattrass, MD, FRCS(C), FRACS1,
Pam Thomason, MPhysio1,
Rory Wolfe, PhD4 and
Dinah Reddihough, MD, FRACP, FAFRM1
1 Departments of Orthopaedics (H.K.G., F.D., G.N., and P.T.) and Developmental Medicine (D.R.), The Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia. E-mail address for H.K. Graham: kerr.graham{at}rch.org.au
2 Murdoch Childrens Research Institute, Flemington Road, Parkville, Victoria 3052, Australia
3 Sydney Children's Hospital, High Street, Randwick, New South Wales 2031, Australia
4 Department of Epidemiology and Preventive Medicine, School of Applied Clinical and Public Health Sciences, Monash University, Alfred Hospital, Commercial Road, Melbourne, Victoria 3004, Australia
Investigation performed at The Royal Children's Hospital, Victoria; Calvary Healthcare, Tasmania; Princess Margaret Hospital, Perth, Western Australia; and Sydney Children's Hospital, New South Wales, Australia
Disclosure: In support of their research for or preparation of this work, one or more of the authors received, in any one year, outside funding or grants in excess of $10,000 from The National Health and Medical Research Council of Australia (NHMRC 980753), CAMP Scandinavia PLC, Allergan PLC, the Royal Children's Hospital Foundation (Melbourne), The Sydney Children's Hospital Foundation, The Royal Hobart Hospital Research Foundation, Calvary Healthcare Tasmania, The Australian Physiotherapy Association, the Australian Orthopaedic Association, and the Murdoch Childrens Research Institute. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of their immediate families, are affiliated or associated.
A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our quarterly CD-ROM (call our subscription department, at 781-449-9780, to order the CD-ROM).
Background: Cerebral palsy is the most common cause of childhood physical disability in developed countries, affecting two children per 1000 live births. Hip displacement affects about one-third of children with cerebral palsy and may result in pain, deformity, and impaired function. The prevention of hip displacement has not been studied in a randomized trial as far as we know.
Methods: A randomized, controlled trial was conducted to examine the effect of intramuscular injections of botulinum toxin A combined with use of a variable hip abduction brace on the progression of hip displacement in children with cerebral palsy. The patients in the treatment group received injections of botulinum toxin A to the adductor and hamstring muscles every six months for three years and were prescribed a hip abduction brace to be worn for six hours per day. In the control group, no hip bracing was used nor were injections performed. The primary outcome measure was hip displacement from the acetabulum as determined by serial measurements of the migration percentage.
Results: Ninety children with bilateral cerebral palsy and so-called hips at risk (a migration percentage of >10% but <40%) were entered into the study. Fifty-nine patients were boys, and the mean age was three years. Progressive hip displacement, as determined by serial measurements of the migration percentage, was found in both the treatment and control groups. The rate of hip displacement was reduced in the treatment group by 1.4% per year (95% confidence interval, –0.6% to 3.4%; p = 0.16) when weighted for the uncertainty in rates due to the differing numbers of migration percentage measurements per subject.
Conclusions: There may be a small treatment benefit for the combined intervention of intramuscular injection of botulinum toxin A and abduction hip bracing in the management of spastic hip displacement in children with cerebral palsy. However, progressive hip displacement continued to occur in the treatment group, and our data do not support recommending this treatment.
Level of Evidence: Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.

CiteULike Connotea Del.icio.us Facebook Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Albavera-Hernandez, J. M Rodriguez, and A. J Idrovo
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials
Clinical Rehabilitation,
May 1, 2009;
23(5):
394 - 407.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Kim and K. J. Noonan
What's New in Pediatric Orthopaedics
J. Bone Joint Surg. Am.,
March 1, 2009;
91(3):
743 - 751.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Seyler, B. P. Smith, D. R. Marker, J. Ma, J. Shen, T. L. Smith, M. A. Mont, K. Kolaski, and L. A. Koman
Botulinum Neurotoxin as a Therapeutic Modality in Orthopaedic Surgery: More Than Twenty Years of Experience
J. Bone Joint Surg. Am.,
November 1, 2008;
90(Supplement_4):
133 - 145.
[Full Text]
[PDF]
|
 |
|
|